Non profit organisation Accumulus Synergy and the Coalition for Epidemic Preparedness Innovations (CEPI) have partnered to accelerate global access to vaccines though a cloud-based data sharing platform.
The initiative, which was made possible through USD $19.1m of funding provided by CEPI, will involve the further development of the digital technology by Accumuls Synergy, which aims to enable regulators to simultaneously access safety and efficacy data.
By providing easy access to such information, regulatory boards can make informed decisions on whether to approve a vaccine quickly and effectively — potentially saving lives in the event of another global pandemic.
Preparing regulators for future health events
During the COVID-19 pandemic, it became apparent that there was a significant need to optimise the regulatory process, allowing the pharmaceutical industry to provide patients with potentially life-saving vaccines and health technologies.
Accumulus Synergy identified that the approval process was generally limited by the duplication of efforts across global regulatory boards, the limited capacity of regualrors and the inequitable access to data required to approve medicines in the Global South.
There was also little sharing between regulatory authorities.
Together, CEPI and Accumuls Synergy aim to improve the 'readiness' of regulators globally through their new framework.
By utilising Accumuls Syngery's cloud-based, real-time collaboration tool, all regulators can gain access to the information necessary for vaccine approval in public health emergencies.
Pilot begins
To trial the platform, Accumulus will make a pilot version available to seven regulatory authorities, allowing the NPO to explore the technology's potential and what needs to be altered.
Accumulus' technology will also be available at a low price for regulatory boards in the Global South — enhancing developer accessibility within this region.
By providing resource-limited countries with cloud technology, all regions — regardless of economic status — can gain rapid access to key vaccines.
Director and Global Head of Regulatory Affairs and Quality at CEPI, Adam Hacker, commented: “The CEPI-Accumulus partnership provides a unique solution to the challenges of pandemic preparedness by enabling seamless collaboration between regulatory authorities, industry stakeholders, and global health organisations across the world,”
“The platform will be instrumental in managing disparate regulatory systems by streamlining and expediting access to crucial information needed to rapidly approve potentially lifesaving vaccines, helping us to stay ahead in the fight against pandemics.”
“Our partnership with CEPI is about more than just readiness; it's about creating a cohesive, global response network that leaves no one behind,” added Frank Nogueira, CEO of Accumulus.
“Together, we are creating a new paradigm for emergency preparedness—one that prioritises speed, accuracy and global coordination. With CEPI’s financial support, we will continue advancing our platform to ensure critical therapies reach those who need them faster than ever before.”
This level of preparedness will support CEPI’s 100 Days Mission, a goal—embraced by leaders of the G7 and G20—to deliver pandemic-beating vaccines in as little as 100 Days.